0001008586
false
0001008586
2023-09-13
2023-09-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 13, 2023
Streamline
Health Solutions, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
0-28132 |
|
31-1455414 |
(State or other jurisdiction of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
2400
Old Milton Pkwy., Box 1353
Alpharetta,
GA 30009
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (888) 997-8732
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, $0.01 par value |
|
STRM |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
2.02 |
Results
of Operations and Financial Condition. |
On
September 13, 2023, Streamline Health Solutions, Inc. (the “Company”) issued a press release announcing second quarter fiscal
2023 financial results for the quarter ended July 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
The
information contained in this Item 2.02, as well as Exhibit 99.1 referenced herein, is being “furnished” and, as such, shall
not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended,
unless the Company expressly so incorporates such information by reference.
Item
9.01 |
Financial
Statements and Exhibits. |
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
STREAMLINE
HEALTH SOLUTIONS, INC. |
|
|
Date:
September 13, 2023 |
By: |
/s/
Thomas J. Gibson |
|
|
Thomas
J. Gibson |
|
|
Chief
Financial Officer |
Exhibit
99.1
Streamline
Health® Reports Fiscal Second Quarter Financial Results
13%
growth of SaaS revenue in the first half of fiscal 2023 compared to the first half of fiscal 2022
Atlanta,
GA, September 13, 2023 (Globe Newswire) – Streamline Health Solutions, Inc. (“Streamline” or the “Company”)
(Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve
financial performance, today announced financial results for the second quarter of 2023 which ended July
31, 2023.
Fiscal
Second Quarter and Six Months Ended July 31, 2023 GAAP Financial Results
The
following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”).
Total
revenue for the second quarter of fiscal 2023 was $5.8 million as compared to $6.0 million during the second quarter of fiscal 2022.
For the six months ended July 31, 2023, revenue totaled $11.1 million as compared to $11.9 million during the same period of fiscal 2022.
The change in total revenue was attributable to lower professional services revenue offset by higher SaaS revenue. As previously reported,
the Company had a large professional services contract which did not renew at the end of its 2022 fiscal year. This professional services
product is not expected to be part of the Company’s core business going forward.
During
the second quarter and first six months of fiscal 2023, SaaS revenue grew $0.4 million and $0.8 million, respectively, as compared to
the prior year periods.
Net
loss for the second quarter of fiscal 2023 was ($2.5 million) compared to a net a loss of ($3.3 million) during the second quarter of
fiscal 2022. For the first six months of fiscal 2023, net loss totaled ($5.4 million) compared to a net loss of ($6.1 million) during
the first six months of fiscal 2022. The improvement in net loss was the result of lower headcount associated with the non-renewal of
a large professional services contract, as well as cost savings achieved through the previously announced integration of the Avelead
and eValuator divisions and non-cash valuation adjustments. The Company believes the decreased net loss on lower total revenue demonstrates
the value of growing our high-margin SaaS business.
Fiscal
Second Quarter and Six Months Ended July 31, 2023 Non-GAAP Financial Results
Adjusted
EBITDA for the second quarter of fiscal 2023 was ($0.9 million) compared to ($1.1 million) during the second quarter of fiscal 2022.
For the six months ended July 31, 2023, adjusted EBITDA was ($2.2 million) compared to ($2.4 million) during the six months ended July
31, 2022.
As
of July 31, 2023, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was $17.6 million compared to $17.2
million as of January 31, 2023. $3.4 million of the Booked SaaS ACV was unimplemented as of July 31, 2023. Booked SaaS ACV represents
the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented as of the measurement date,
assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the
Company has knowledge of the non-renewal.
Management
Commentary
“The
Streamline Health team has made significant progress as an organization in fiscal 2023. Our innovation team made significant advancements
during the first half of the year which we expect to result in improved implementation timelines and lower expenses, while the services
team has ensured our clients are receiving world-class support regardless of solution,” stated Tee Green, Chief Executive Officer,
Streamline Health. “While our growth team has been encumbered by significant macro headwinds, health systems remain excited about
the potential to transform their revenue cycle with our suite of pre-bill solutions which ensure they are accurately paid for all of
the care they’ve provided.”
Conference
Call
The
Company will conduct a conference call on Thursday, September 14, 2023, at 9:00 AM ET to review results and provide a corporate update.
Interested parties can access the call by joining the live webcast: click here to register. You can also join by phone by dialing
877-407-8291. Following the conference call, management will host one-on-one meetings at the Lake Street Capital Markets 7th
Annual Best Ideas Growth Conference in New York, NY.
A
replay of the conference call will be available from Thursday, September 14, 2023, at 12:00 PM ET to Thursday, September 21, 2023, at
12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13741041. An online replay of the presentation will also be available
for six months following the presentation in the Investor Relations section of the Streamline website, www.streamlinehealth.net.
About
Streamline Health
Streamline
Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance.
We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial
performance across the enterprise. For more information, visit www.streamlinehealth.net.
Non-GAAP
Financial Measures
Streamline
reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s
management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a
non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding
the performance of Streamline’s business operations.
Streamline
defines “adjusted EBITDA” as net earnings (loss) plus interest expense, tax expense, depreciation and amortization expense
of tangible and intangible assets, share-based compensation expense, significant non-recurring operating expenses, and transactional
related expenses including: gains and losses on debt and equity conversions, associate severances and related restructuring expenses,
associate inducements, and professional and advisory fees. A table reconciling this measure to “loss from continuing operations”
is included in this press release.
Booked
SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as
of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its
existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does
not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by
contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue.
There is no GAAP measure comparable to Booked SaaS ACV.
Safe
Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements
made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks,
uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking
statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding
the Company’s growth prospects, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, anticipated
cost savings, expected improved implementation timelines and lower expenses for our clients, industry trends and market growth, adjusted
EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited
to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto,
the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the
impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current
solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company
to generate cash from operations, the availability of additional debt and equity financing to fund the Company’s ongoing operations,
the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions
from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding
affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel
for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting
policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or
other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets
in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities,
and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission.
Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only
as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking
statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated
events, except as required by law.
Company
Contact
Jacob
Goldberger
Director,
Investor Relations and FP&A
303-887-9625
jacob.goldberger@streamlinehealth.net
STREAMLINE
HEALTH SOLUTIONS, INC.
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(rounded
to the nearest thousand dollars, except share and per share information)
| |
Three Months Ended July 31, | | |
Six Months Ended July 31, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenues: | |
| | | |
| | | |
| | | |
| | |
Software as a service | |
$ | 3,531,000 | | |
$ | 3,117,000 | | |
$ | 6,706,000 | | |
$ | 5,948,000 | |
Maintenance and support | |
| 1,100,000 | | |
| 1,118,000 | | |
| 2,257,000 | | |
| 2,228,000 | |
Professional fees and licenses | |
| 1,139,000 | | |
| 1,757,000 | | |
| 2,139,000 | | |
| 3,751,000 | |
Total revenues | |
| 5,770,000 | | |
| 5,992,000 | | |
| 11,102,000 | | |
| 11,927,000 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Cost of software as a service | |
| 1,893,000 | | |
| 1,532,000 | | |
| 3,482,000 | | |
| 3,029,000 | |
Cost of maintenance and support | |
| 32,000 | | |
| 90,000 | | |
| 121,000 | | |
| 136,000 | |
Cost of professional fees and licenses | |
| 1,022,000 | | |
| 1,582,000 | | |
| 2,130,000 | | |
| 3,248,000 | |
Selling, general and administrative expense | |
| 4,107,000 | | |
| 3,934,000 | | |
| 7,913,000 | | |
| 8,435,000 | |
Research and development | |
| 1,305,000 | | |
| 1,461,000 | | |
| 3,006,000 | | |
| 2,773,000 | |
Acquisition-related costs | |
| 9,000 | | |
| 49,000 | | |
| 44,000 | | |
| 139,000 | |
Total operating expenses | |
| 8,368,000 | | |
| 8,648,000 | | |
| 16,696,000 | | |
| 17,760,000 | |
Operating loss | |
| (2,598,000 | ) | |
| (2,656,000 | ) | |
| (5,594,000 | ) | |
| (5,833,000 | ) |
Other (expense) income: | |
| | | |
| | | |
| | | |
| | |
Interest expense | |
| (267,000 | ) | |
| (189,000 | ) | |
| (515,000 | ) | |
| (321,000 | ) |
Acquisition earnout valuation adjustments | |
| 359,000 | | |
| (475,000 | ) | |
| 723,000 | | |
| 25,000 | |
Other | |
| (1,000 | ) | |
| 50,000 | | |
| 31,000 | | |
| 83,000 | |
Loss before income taxes | |
| (2,507,000 | ) | |
| (3,270,000 | ) | |
| (5,355,000 | ) | |
| (6,046,000 | ) |
Income tax expense | |
| (8,000 | ) | |
| (2,000 | ) | |
| (61,000 | ) | |
| (13,000 | ) |
Net loss | |
$ | (2,515,000 | ) | |
$ | (3,272,000 | ) | |
$ | (5,416,000 | ) | |
$ | (6,059,000 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and Diluted Earnings Per Share: | |
| | | |
| | | |
| | | |
| | |
Net loss per common share – basic and diluted | |
$ | (0.04 | ) | |
$ | (0.07 | ) | |
$ | (0.10 | ) | |
$ | (0.13 | ) |
Weighted average number of common shares – basic and diluted | |
| 56,357,684 | | |
| 47,231,296 | | |
| 56,164,282 | | |
| 47,129,879 | |
STREAMLINE
HEALTH SOLUTIONS, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(rounded
to the nearest thousand dollars, except share and per share information)
| |
July 31, 2023 | | |
January 31, 2023 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 4,087,000 | | |
$ | 6,598,000 | |
Accounts receivable, net of allowance for credit losses of $94,000 and $132,000, respectively | |
| 2,790,000 | | |
| 7,719,000 | |
Contract receivables | |
| 940,000 | | |
| 960,000 | |
Prepaid and other current assets | |
| 895,000 | | |
| 710,000 | |
Total current assets | |
| 8,712,000 | | |
| 15,987,000 | |
Non-current assets: | |
| | | |
| | |
Property and equipment, net of accumulated amortization of $266,000 and $246,000 respectively | |
| 106,000 | | |
| 79,000 | |
Right-of use asset for operating lease | |
| — | | |
| 32,000 | |
Capitalized software development costs, net of accumulated amortization of $7,107,000 and $6,224,000, respectively | |
| 6,105,000 | | |
| 5,846,000 | |
Intangible assets, net of accumulated amortization of $3,527,000 and $2,627,000, respectively | |
| 13,893,000 | | |
| 14,793,000 | |
Goodwill | |
| 23,089,000 | | |
| 23,089,000 | |
Other | |
| 1,410,000 | | |
| 1,695,000 | |
Total non-current assets | |
| 44,603,000 | | |
| 45,534,000 | |
Total assets | |
$ | 53,315,000 | | |
$ | 61,521,000 | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 657,000 | | |
$ | 626,000 | |
Accrued expenses | |
| 1,939,000 | | |
| 3,265,000 | |
Current portion of term loan | |
| 1,000,000 | | |
| 750,000 | |
Deferred revenues | |
| 6,724,000 | | |
| 8,361,000 | |
Current portion of operating lease obligation | |
| — | | |
| 35,000 | |
Acquisition earnout liability | |
| 3,015,000 | | |
| 3,738,000 | |
Total current liabilities | |
| 13,335,000 | | |
| 16,775,000 | |
Non-current liabilities: | |
| | | |
| | |
Term loan, net of current portion and deferred financing costs | |
| 8,517,000 | | |
| 8,964,000 | |
Deferred revenues, less current portion | |
| 212,000 | | |
| 167,000 | |
Other non-current liabilities | |
| 147,000 | | |
| 104,000 | |
Total non-current liabilities | |
| 8,876,000 | | |
| 9,235,000 | |
Total liabilities | |
| 22,211,000 | | |
| 26,010,000 | |
Stockholders’ equity: | |
| | | |
| | |
Common stock, $0.01 par value per share, 85,000,000 shares authorized; 58,895,071 and 57,567,210 shares issued and outstanding, respectively | |
| 589,000 | | |
| 576,000 | |
Additional paid in capital | |
| 132,933,000 | | |
| 131,973,000 | |
Accumulated deficit | |
| (102,418,000 | ) | |
| (97,038,000 | ) |
Total stockholders’ equity | |
| 31,104,000 | | |
| 35,511,000 | |
Total liabilities and stockholders’ equity | |
$ | 53,315,000 | | |
$ | 61,521,000 | |
STREAMLINE
HEALTH SOLUTIONS, INC.
UNAUDITED
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(rounded
to the nearest thousand dollars)
| |
Six Months Ended July 31, | |
| |
2023 | | |
2022 | |
Net loss | |
$ | (5,416,000 | ) | |
$ | (6,059,000 | ) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 2,134,000 | | |
| 2,199,000 | |
Acquisition earnout valuation adjustments | |
| (723,000 | ) | |
| (25,000 | ) |
Provision for deferred income taxes | |
| 43,000 | | |
| — | |
Share-based compensation expense | |
| 1,109,000 | | |
| 657,000 | |
Provision for credit losses | |
| — | | |
| 21,000 | |
Changes in assets and liabilities: | |
| | | |
| | |
Accounts and contract receivables | |
| 4,985,000 | | |
| 329,000 | |
Other assets | |
| (146,000 | ) | |
| (742,000 | ) |
Accounts payable | |
| 31,000 | | |
| (109,000 | ) |
Accrued expenses and other liabilities | |
| (1,361,000 | ) | |
| 364,000 | |
Deferred revenue | |
| (1,592,000 | ) | |
| 414,000 | |
Net cash used in operating activities | |
| (936,000 | ) | |
| (2,951,000 | ) |
Cash flows from investing activities: | |
| | | |
| | |
Purchases of property and equipment | |
| (47,000 | ) | |
| (10,000 | ) |
Capitalization of software development costs | |
| (1,026,000 | ) | |
| (871,000 | ) |
Net cash used in investing activities | |
| (1,073,000 | ) | |
| (881,000 | ) |
Cash flows from financing activities: | |
| | | |
| | |
Repayment of bank term loan | |
| (250,000 | ) | |
| — | |
Payments related to settlement of employee share-based awards | |
| (252,000 | ) | |
| (141,000 | ) |
Other | |
| — | | |
| 6,000 | |
Net cash used in financing activities | |
| (502,000 | ) | |
| (135,000 | ) |
Net decrease in cash and cash equivalents | |
| (2,511,000 | ) | |
| (3,967,000 | ) |
Cash and cash equivalents at beginning of period | |
| 6,598,000 | | |
| 9,885,000 | |
Cash and cash equivalents at end of period | |
$ | 4,087,000 | | |
$ | 5,918,000 | |
STREAMLINE
HEALTH SOLUTIONS, INC.
NEW
BOOKINGS
(Unaudited,
rounded to the nearest thousand dollars)
| |
July 31, 2023 | |
| |
Three Months Ended | | |
Six Months Ended | |
Software as a service | |
| 765,000 | | |
| 2,841,000 | |
Maintenance and support | |
| - | | |
| - | |
Professional fees and licenses | |
| 266,000 | | |
| 364,000 | |
Q2 2023 Bookings | |
$ | 1,031,000 | | |
| 3,205,000 | |
Q2 2022 Bookings | |
$ | 5,152,000 | | |
| 14,015,000 | |
STREAMLINE
HEALTH SOLUTIONS, INC.
RECONCILIATION
OF NET LOSS TO NON-GAAP ADJUSTED EBITDA
(Unaudited,
in thousands)
| |
Three Months Ended | | |
Six Months Ended | |
| |
July 31, 2023 | | |
July 31, 2022 | | |
July 31, 2023 | | |
July 31, 2022 | |
Adjusted EBITDA Reconciliation | |
| | | |
| | | |
| | | |
| | |
Loss from continuing operations | |
$ | (2,515 | ) | |
$ | (3,272 | ) | |
$ | (5,416 | ) | |
$ | (6,059 | ) |
Interest expense | |
| 267 | | |
| 189 | | |
| 515 | | |
| 321 | |
Income tax expense | |
| 8 | | |
| 2 | | |
| 61 | | |
| 13 | |
Depreciation and amortization | |
| 1,050 | | |
| 1,076 | | |
| 2,081 | | |
| 2,159 | |
EBITDA | |
$ | (1,190 | ) | |
$ | (2,005 | ) | |
$ | (2,759 | ) | |
$ | (3,566 | ) |
Share-based compensation expense | |
| 537 | | |
| 331 | | |
| 1,109 | | |
| 657 | |
Non-cash valuation adjustments | |
| (359 | ) | |
| 475 | | |
| (723 | ) | |
| (25 | ) |
Acquisition-related costs, severance, and transaction-related bonuses | |
| 119 | | |
| 122 | | |
| 176 | | |
| 623 | |
Other non-recurring charges | |
| — | | |
| (19 | ) | |
| (33 | ) | |
| (67 | ) |
Adjusted EBITDA | |
$ | (893 | ) | |
$ | (1,096 | ) | |
$ | (2,230 | ) | |
$ | (2,378 | ) |
v3.23.2
Cover
|
Sep. 13, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Sep. 13, 2023
|
Entity File Number |
0-28132
|
Entity Registrant Name |
Streamline
Health Solutions, Inc.
|
Entity Central Index Key |
0001008586
|
Entity Tax Identification Number |
31-1455414
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2400
Old Milton Pkwy.
|
Entity Address, Address Line Two |
Box 1353
|
Entity Address, City or Town |
Alpharetta
|
Entity Address, State or Province |
GA
|
Entity Address, Postal Zip Code |
30009
|
City Area Code |
(888)
|
Local Phone Number |
997-8732
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.01 par value
|
Trading Symbol |
STRM
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Streamline Health Soluti... (NASDAQ:STRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Streamline Health Soluti... (NASDAQ:STRM)
Historical Stock Chart
From Jul 2023 to Jul 2024